| Autor: |
Thamm, Douglas H., MacEwen, E. Gregory, Phillips, Brenda S., Hershey, A. Elizabeth, Burgess, Kristine M., Pettit, George R., Vail, David M. |
| Předmět: |
|
| Zdroj: |
Cancer Chemotherapy & Pharmacology; Mar2002, Vol. 49 Issue 3, p251-255, 5p |
| Abstrakt: |
Purpose: To evaluate the short-term adverse effects of administration of dolastatin-10 (Dol-10) to dogs with spontaneously occurring malignant tumors. Methods: A total of 34 tumor-bearing dogs were given Dol-10 as a rapid intravenous bolus every 14 days at starting dosages ranging from 200 to 350 µg/m2. Acute and short-term adverse effects, antitumor response, and duration of response were characterized. Results: The maximum tolerated dose varied greatly from patient to patient, but a reasonable starting dose for further studies was established at 300 µg/m2. The median number of treatments per dog was 2 (range 1 to 17). Granulocytopenia was the dose-limiting toxicity. The overall response rate was 3%, consisting of a complete and durable (30 months) response in a dog with high-grade malignant lymphoma that was refractory to standard therapy. Two minor or transient responses were observed, and two dogs experienced disease stabilization for 8 and 16 weeks. Conclusions: Dol-10 appears to be well tolerated in tumor-bearing dogs at doses approaching those tolerated by humans. The clinical activity observed in dogs with non-Hodgkin's lymphoma warrants further investigation. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink